Vivanza Biosciences Ltd

Vivanza Biosciences Ltd has confirmed that the statements of Variation and Deviation under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are not applicable to the company. This is because Vivanza Biosciences has not raised any further funds through Public Issue, Rights Issue, or Preferential Issue. Consequently, the company is not required to provide the Statement of Deviation(s) or Variation(s) for the period.

Vivanza Biosciences Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut from October 1, 2026, until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. During this period, no transactions involving the company's securities are permitted for insiders.

Vivanza Biosciences Ltd has announced its 44th Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 03:30 P.M. (IST) via Video Conference/Other Audio Visual Means. The company is sending the Notice of the 44th AGM and the Annual Report for the Financial Year 2025-2026 to shareholders electronically. Shareholders without registered email addresses will receive a weblink to access these documents. The Annual Report covers corporate information, the Director's Report, financial statements (standalone and consolidated), auditor's reports, and management discussion and analysis.

Vivanza Biosciences Ltd has announced its 44th Annual General Meeting (AGM) will be held on Friday, September 11, 2026, at 03:30 P.M. (IST) via Video Conference/Other Audio Visual Means. The company is also releasing its Annual Report for the Financial Year 2025-26. Both the Notice of the AGM and the Annual Report are being sent to shareholders in electronic mode, with a weblink provided for those who have not registered their email addresses. The documents will also be available on the company's website. The Annual Report details corporate information, the AGM notice, Director's Report, financial statements (standalone and consolidated), auditor's reports, and management discussion and analysis.

Vivanza Biosciences Ltd's Board of Directors met on August 17, 2026, approving key corporate actions. The Board greenlit the Director's Report and Secretarial Audit Report for FY25-26. They also approved convening the 44th Annual General Meeting (AGM) and appointed a scrutinizer for e-voting. A cut-off date of September 4, 2026, was set for AGM eligibility. Furthermore, the Board approved adopting a new Memorandum and Articles of Association, subject to shareholder consent. Proposals to seek member approval for material related party transactions, increased borrowing limits under Section 180(1)(c), and financial transactions under Section 185 were also approved. Additionally, proposals for investments, loans, guarantees, or securities exceeding limits under Section 186 were approved for member consent.

Vivanza Biosciences Ltd has announced a Board of Directors meeting scheduled for August 17, 2026. The primary agenda items include the consideration and approval of the Director's Report and Secretarial Audit Report for FY 2025-26. The board will also discuss and approve the convening of the 44th Annual General Meeting (AGM), appoint a scrutinizer for e-voting, and fix the 'Cut-Off Date' for the AGM as September 04, 2026. Additionally, proposals for adopting amended Memorandum and Articles of Association, seeking member approval for proposed borrowings under Section 180(1)(c), transactions under Section 185, and investments/loans/guarantees under Section 186 of the Companies Act, 2013 will be considered.

Vivanza Biosciences Ltd has issued a clarification regarding the submission of the statement of deviation or variation from the proceeds of public/rights/preferential issues. The company confirms that it has not raised any funds through these methods. Consequently, the statement of deviation or variation is not applicable to Vivanza Biosciences, and they have informed the exchange accordingly. This filing addresses regulatory requirements under SEBI (LODR) Regulations, 2015.

Vivanza Biosciences Ltd announced the approval of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors convened on August 7, 2026, to review and approve these results, along with the accompanying Limited Review Report. The meeting also addressed disclosures of interest from Directors and confirmations of independence from Independent Directors as per relevant Companies Act and SEBI regulations. The financial results were prepared in accordance with Indian Accounting Standard 34 for interim financial reporting.

Vivanza Biosciences Ltd announced the approval of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors convened on August 7, 2026, to review and approve these results, along with the accompanying Limited Review Report. The meeting also addressed disclosures of interest from Directors and confirmations of independence from Independent Directors as per relevant Companies Act and SEBI regulations. The financial results were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) for interim financial reporting.

Vivanza Biosciences Ltd announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results, along with the limited review report, during a meeting held on August 7, 2026. The company also noted disclosures of interest from directors and confirmations of independence from independent directors as per regulatory requirements. The meeting commenced at 12:45 PM and concluded at 1:00 PM.